Albertinen-Krankenhaus/Albertinen-Haus gGmbH

At Albertinen-Krankenhaus/Albertinen-Haus gGmbH in Hamburg, clinical trials in female urogenital diseases focus mainly on ovarian cancer and related gynecologic malignancies. The studies are designed to improve treatment effectiveness, extend progression-free survival, and refine first-line and maintenance therapy approaches for women with advanced disease.

• Advanced high-grade epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
• Platinum-resistant ovarian cancer and FRα-defined disease groups
• Testing new treatment combinations and comparing them with current standards to improve disease control

The site’s research in this area emphasizes better outcomes for patients with newly diagnosed and recurrent gynecologic cancers, with a strong focus on evaluating more effective systemic therapies.

Clinical research in neoplasms also includes breast cancer, especially hormone receptor positive, HER2 negative disease and ER+/HER2- early breast cancer. These trials aim to lower recurrence risk, improve long-term disease control, and assess whether newer endocrine-based strategies can perform better than standard treatment.

• Early breast cancer with a focus on preventing recurrence
• Locally advanced and metastatic breast cancer in hormone receptor positive, HER2 negative disease
• Evaluating improved endocrine-based treatment options and combination approaches

This research reflects a broader effort at the site to personalize treatment for breast cancer patients while maintaining effectiveness and reducing the chance of relapse.

The site also takes part in oncology trials for Hodgkin lymphoma, showing that its cancer research extends beyond gynecologic and breast malignancies. These studies are aimed at improving treatment balance by reducing treatment-related burden while preserving anti-cancer effectiveness.

• Advanced stage Hodgkin lymphoma
• Comparing treatment strategies to support better tolerability and disease control
• Assessing whether newer approaches can maintain effectiveness with less toxicity

At this hospital/clinic, the oncology portfolio combines efforts to improve survival outcomes with a strong interest in safer, more patient-friendly cancer care.